Analog vs Agonist vs Mimetic vs Secretagogue

Read any peptide description and you’ll hit the same four words: analog, agonist, mimetic, secretagogue. They get used almost interchangeably in marketing, which is a shame, because they answer completely different questions. Two of them describe what a molecule is built from. Two of them describe what a molecule does. Once you separate those, a lot of confusing product copy suddenly makes sense — and you stop assuming that four impressive-sounding labels mean four different benefits. This is a plain-language walk through the peptide terms explained the way a pharmacologist would, and you can keep the short definitions on hand in our peptide research glossary.

Structure words vs action words

Here’s the mental model to hold the whole time:

• Analog and mimetic are about resemblance — how the molecule is designed relative to something natural.
• Agonist and secretagogue are about behavior — what the molecule causes to happen in the body.

An analog is defined by structure (a tweaked copy of a known molecule); an agonist is defined by action (it switches a receptor on).

Because these are different axes, a single compound routinely wears several labels. Semaglutide, for instance, is both a GLP-1 analog and a GLP-1 receptor agonist and an incretin mimetic — those aren’t three claims, they’re three true statements about the same molecule from three angles.

Analog: a tweaked copy

An analog (British spelling: analogue) is a molecule whose structure is deliberately based on another, known molecule, with small changes. The changes are the point: they usually make the copy more stable, longer-lasting, or more selective than the original. Crucially, the pharmacology definition is about structure, not effect — an analog can behave very differently from its parent, and a structural analog of an activating molecule can even end up blocking the same receptor.

Semaglutide is a clean example. Its FDA prescribing information puts it plainly: “Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1.” The label describes the edits that get it there — a substitution at position 8 to protect against breakdown by the enzyme DPP-4, and a C18 fatty di-acid attached at position 26 through a spacer, which lets the molecule bind albumin. Same backbone, engineered edits, dramatically different half-life.

Agonist: it turns the switch on

An agonist is defined by what it does at a receptor: it binds and activates it, increasing that receptor’s activity. Think of the receptor as a lock and the agonist as a key that both fits and turns.

The natural contrast is the antagonist — a molecule that binds the same lock but doesn’t turn it, and in doing so blocks the real key from getting in. (There are in-between cases: a partial agonist turns the switch only part-way, and some structural analogs of agonists behave as antagonists.) That agonist/antagonist split is the backbone of receptor pharmacology, and we unpack it further in the plain-language primer on receptor agonists vs antagonists.

The key insight: “agonist” is silent about structure. An agonist can be a peptide, a small molecule, or the body’s own hormone. All that matters is that it activates the receptor.

Mimetic: it copies the effect

A mimetic is a molecule that reproduces the effect of a natural substance, often without copying its exact chemistry. The most useful category here is the peptidomimetic — a compound engineered to mimic the three-dimensional shape and action of a bioactive peptide while shedding the fragile peptide bonds, so it survives digestion and lasts longer. A peptidomimetic can act as either an agonist or an antagonist at its target.

In the metabolic world you’ll see the phrase incretin mimetic used for the GLP-1 drugs, because they reproduce the action of the body’s incretin hormones (GLP-1 and GIP). Note how “mimetic” and “agonist” overlap without being identical: the drug is a mimetic because it copies the hormone’s effect, and it does that copying by being a receptor agonist. The mimetic label describes the goal; the agonist label describes the mechanism.

Secretagogue: it makes your body do the work

A secretagogue is the odd one out, and the most misunderstood. It doesn’t supply the active substance — it prompts your own body to secrete it. (The word literally means “leading to secretion.”)

The clearest peptide example is the growth hormone secretagogue (GHS) family. Compounds like GHRP-6 and GHRP-2 don’t contain growth hormone and don’t act on GH receptors. Instead they act on a separate receptor, cloned by a Merck group in 1996 from the pituitary and hypothalamus of swine and humans and named the growth hormone secretagogue receptor (GHS-R) precisely because it was the target these secretagogues were hitting. Three years later a Japanese group purified its natural ligand from rat stomach — a 28-amino-acid acylated peptide they called ghrelin — which is why GHS-R is now usually just called the ghrelin receptor. Activating it prompts the pituitary to release your own growth hormone. Same idea for GHRH analogs like sermorelin: they nudge the natural release machinery rather than replacing the product.

This indirect route is why secretagogues behave differently from direct hormone dosing — the response is shaped by your own physiology, feedback loops, and how much hormone you have to release in the first place. Even GLP-1 counts as a natural insulin secretagogue, but a glucose-dependent one, which is part of why the GLP-1 drugs carry a lower hypoglycemia risk than older sulfonylurea secretagogues that force insulin out regardless of blood sugar.

Putting it together

Term	Answers the question	Defined by	Example
Analog	What is it built from?	Structure (tweaked copy)	Semaglutide (GLP-1 analog)
Agonist	What does it do at the receptor?	Action (activates it)	Any GLP-1 receptor agonist
Mimetic	What effect does it copy?	Function (reproduces an effect)	Incretin mimetics; peptidomimetics
Secretagogue	How does it act?	Indirect (triggers your own release)	GHRP-6, sermorelin (GH secretagogues)

Notice that the columns don’t compete — they describe different facets. Asking “is it an analog or an agonist?” is like asking whether a car is “red or fast.” It can be both.

The honest caveat

These four words describe design intent and mechanism. They say nothing about whether a compound is effective, safe, or legal. Semaglutide-class drugs are approved and heavily studied; most of the research peptides that borrow this vocabulary are not approved for human use and rest on animal or preclinical data that may not translate to people — a gap we cover in animal data vs human data: the peptide translation gap. A polished label like “GHRH analog and GH secretagogue” is a description of how something is meant to work, not evidence that it does.

Use these terms to read the science more precisely, then judge each compound on its actual data. For quick reference on this and the rest of the vocabulary, keep the peptide research glossary open. This is educational information, not medical advice — consult a qualified clinician before acting on any of it.

Sources

Definitions of agonist, antagonist, and partial agonist are from the MSD Manual’s drug–receptor interactions chapter. The semaglutide figures — 94% sequence homology to human GLP-1, the position-8 and position-26 modifications, and GLP-1 receptor agonism as the mechanism of action — are quoted from the FDA-approved Ozempic prescribing information. The GLP-1 / incretin background and the sulfonylurea comparison are from StatPearls. The growth hormone secretagogue receptor was cloned and named by Howard et al. (Science, 1996); ghrelin was identified as its endogenous ligand by Kojima et al. (Nature, 1999).

Peptidomimetic is used here in its standard medicinal-chemistry sense — a compound engineered to reproduce a peptide’s shape and action without its peptide bonds. That is a definition, not a research finding, and no source is cited for it.

• Drug–Receptor Interactions, MSD Manual Professional Edition
• Glucagon-Like Peptide-1 Receptor Agonists, StatPearls, NCBI Bookshelf
• OZEMPIC (semaglutide) injection — FDA prescribing information, DailyMed
• Howard AD et al., “A receptor in pituitary and hypothalamus that functions in growth hormone release,” Science, 1996
• Kojima M et al., “Ghrelin is a growth-hormone-releasing acylated peptide from stomach,” Nature, 1999